Duchenne muscular dystrophy causes progressive muscle degeneration and weakness, but physical exercise should still be part of a comprehensive treatment strategy. Duchenne muscular dystrophy (DMD ...

Posters presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference highlight the complex care needs and physical activity barriers for individuals with myotonic dystrophy.

An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment.

A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...

A comprehensive care approach can help people with ambulatory DMD maximize function and retain the ability to walk for as ...

Regenxbio has reported positive interim data from the Phase I/II portion of its Affinity Duchenne study, which is examining ...

Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature ...

The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...

UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...

Solid Biosciences will present Phase 1/2 trial data for SGT-003 gene therapy targeting Duchenne muscular dystrophy at MDA Conference. Solid Biosciences Inc. will present data from its Phase 1/2 ...

In addition to the data presented on nucleoside and/or nucleotide therapy, patient experience data presented highlight the debilitating physical impacts and severe psychological strain associated ...